After launching at the end of 2022, IBSA’s dedicated US authorized generics and complex generics unit, Yaral Pharma, has brought on board another of its parent company’s products.

Marketed as Bhava, Zydus’ bevacizumab rival to Roche’s Avastin begins the firm’s biosimilar journey in the Latin American country.

Endo continues to stride its financial revival path, with the latest plans to list common stock on the NYSE. Also, the firm has just launched a generic tiopronin rival to Travere Therapeutics' Thiola.

Gedeon Richter has revealed that its European filing for a denosumab biosimilar rival to Prolia/Xgeva has been accepted for review by the EMA.

After launching at the end of 2022, IBSA’s dedicated US authorized generics and complex generics unit, Yaral Pharma, has brought on board another of its parent company’s products.

Boehringer Ingelheim is partnering with GoodRx in the US to offer a version of its Humira biosimilar at a 92% discount to the brand’s list price. Generics Bulletin spoke with Chris Marsh, Boehringer’s senior vice president of value and access, about the initiative.

ANI has acquired Alimera Sciences in a move to expand its rare disease business, highlighting its increasing drift from generics.

After announcing a pivot to innovative oncology treatments from biosimilars, Coherus has granted an exclusive license for its novel biologic cancer therapy Loqtorzi to Apotex in Canada.

Sweden’s Xbrane Biopharma has delivered updates for two of its more long-term projects, including a proposed biosimilar to Bristol Myers Squibb’s Opdivo for which it is actively seeking a partner.

Manufacturers should keep a sharp eye on data from contract research organizations, looking for “any irregularities” amid a concerning trend of data integrity issues pertaining to BA/BE studies conducted by certain CROs in India, the director of the FDA’s drug center says.

Just-Evotec Biologics has announced an expansion of its partnership with Sandoz to develop and manufacture biosimilars.

Italy’s Olon Group has acquired French biotech contract development and manufacturing organization GTP Bioways, in a move that Olon says will allow it to “expand and diversify its technological offerings.”

Krka insisted that its margins were “stable and high,” as the Slovenian firm reported another solid quarter.

Teva enjoyed a favorable tax status for years in its domestic Israel. However, after the firm battled in court against challenges to its historic tax payments, Teva has now agreed a three-quarters-of-a-billion dollar settlement agreement with the Israel Tax Authority.

Alvotech has announced its latest European biosimilars partnership, collaborating with Advanz on both 2mg and 8mg aflibercept rivals to Eylea. The deal follows several other recent alliances as well as a raise in Alvotech’s full-year revenues guidance to as much as $500m.

Lotus will look forward to adding ophthalmic and respiratory products to its growing portfolio after striking a deal to swallow up Teva’s operations in Thailand.

Marking a further development in the story of Hyloris’ in-licensing deal with QliniQ, the company’s board has announced significant leadership and organizational changes to address potential concerns.

Guided by the firm’s ‘Vision 2026’ strategy, Fresenius Kabi has tapped Cipla executive Arunesh Verma to lead Fresenius Kabi USA, as former head John Ducker retires after 35 years.

Lupin has selected a CEO to lead its fresh API CDMO business venture, while the UK’s off-patent group BGMA has appointed a new vice-chair. Meanwhile, ChemWerth has welcomed a familiar face as its new president and Coherus has elected a new board member with a focus on immuno-oncology.

A busy couple of weeks for executive appointments in the generics and biosimilars industry has seen Dr Reddy’s name a new North American CEO, Fresenius Kabi appoint a new biopharma chief, Teva recruit a new head of global operations, and more.